Neuroprotective Role of Erythropoietin in Perinatal Asphyxia
NCT ID: NCT02002039
Last Updated: 2016-10-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
100 participants
INTERVENTIONAL
2012-06-30
2016-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Erythropoietin in Management of Neonatal Hypoxic Ischemic Encephalopathy
NCT03163589
Neurological Outcome After Erythropoietin Treatment for Neonatal Encephalopathy
NCT00808704
Neonatal Erythropoietin in Asphyxiated Term Newborns
NCT00719407
Efficacy of Erythropoietin to Improve Survival and Neurological Outcome in Hypoxic Ischemic Encephalopathy
NCT01732146
Erythropoietin in HIE Neonate
NCT06590155
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
erythropoietin, perinatal asphyxia,
Treatment group
Erythropoietin
500 units /kg /day every other day for 5 doses
Normal saline, perinatal asphyxia
Normal saline on alternate days for 5 doses starting from first 6 hours of life
Erythropoietin
500 units /kg /day every other day for 5 doses
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Erythropoietin
500 units /kg /day every other day for 5 doses
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Small for gestational age babies
* Babies with chromosomal anomalies
6 Hours
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sheri Kashmir Institute of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr.Mushtaq
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Feroz Shaheen, MD
Role: STUDY_CHAIR
SKIMS
Prof. WAjid Ali
Role: STUDY_DIRECTOR
SKIMS
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sheri-Kashmir Institute of Medical Sciences
Srinagar, Jammu and Kashmir, India
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Erythropoietin 01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.